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Objective: To assess the effectiveness of a non-pharmacological intervention in patients
with asthma on conventional therapy including inhaled corticosteroid.
Design: A randomised controlled trial of the Buteyko technique in a group of adults with
asthma. The control group was trained by a physiotherapist in breathing and relaxation
techniques.
Setting: A single centre associated with a University-based asthma programme.
Main outcome measure: Asthma control, deﬁned by a composite score based on the
Canadian asthma consensus report 6 months after completion of the intervention.
Results: Both groups showed substantial and similar improvement and a high proportion
with asthma control 6 months after completion of the intervention. In the Buteyko group
the proportion with asthma control increased from 40% to 79% and in the control group
from 44% to 72%. In addition the Buteyko group had signiﬁcantly reduced their inhaled
corticosteroid therapy compared with the control group (p ¼ 0.02). None of the other
differences between the groups at 6 months were signiﬁcant.
Conclusions: Six months after completion of the interventions, a large majority of
subjects in each group displayed control of their asthma with the additional beneﬁt of
reduction in inhaled corticosteroid use in the Buteyko group. The Buteyko technique, an
established and widely recognised intervention, or an intensive programme delivered by aElsevier Ltd. All rights reserved.
funded by an anonymous donor through the Dean’s Ofﬁce, Faculty of Medicine, University of Calgary,
220 8859; fax: +1 403 210 7944.
(R.L. Cowie).
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A randomised controlled trial of the Buteyko technique 727chest physiotherapist appear to provide additional beneﬁt for adult patients with asthma
who are being treated with inhaled corticosteroid.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Asthma is a chronic disease, which affects up to 10% of the
population of Canada.1 The disease cannot be cured, but
randomised clinical trials have shown that with efﬁcacious
medication approximately 70% of those with asthma can
enjoy disease control.2–5 Control of asthma has been deﬁned
as not having any restriction in activities, not waking at
night with asthma, not needing b2 agonist therapy to relieve
symptoms more than 3 times per week, not missing school or
work because of asthma and not having severe exacerba-
tions of asthma.6 Data from several studies in Canada have
shown that only one in three to four people with the disease
enjoy control of their asthma.7–10 It has been stated that
some of the failure to control asthma relates to a wide-
spread fear or dislike of medications, notably inhaled
corticosteroid, which are used to manage asthma.11 This
apprehension has stimulated the development of several
non-pharmaceutical approaches to the management of
asthma. Many of these have been embraced without
objective evidence for their efﬁcacy. The assessment of
many modalities of treatment of asthma has been impeded
by the striking impact of the placebo effect in this
disease.12,13 Improvement in asthma control has often been
attributed to an intervention, which was coincidentally
applied when asthma was improving because of the vari-
able nature of the disease and the phenomenon of
regression to the mean. In other words, those with asthma
will often seek assistance during periods of very poor disease
control. With time their disease will improve (back to its
average state) and any new treatment which was applied is
credited with the improvement. This concern is true also for
the Buteyko breathing technique, which has a dedicated
following, but to date, no rigorous data to support its
efﬁcacy.
The Buteyko breathing technique was developed by
Dr. Konstantin Buteyko, a Russian physician who postulated
that asthma was caused by hyperventilation. He proposed
that all of the manifestations of asthma could be explained
on the basis of low tension of CO2. The Buteyko technique
was developed to train those with asthma to reduce their
ventilation.
There have been several studies, which claim success
using the Buteyko technique,14–16 but these were either
uncontrolled or showed only a trend towards improvement.
Others have studied the technique and concluded that any
beneﬁt is not related to changes in ventilation.17 Three
randomised controlled trials have been published recently:
one comparing the Buteyko method with placebo and with
the Pink City Lung Exerciser,18 one with education and
relaxation classes19 and the third used video instruction in
Buteyko and upper body exercises.20 The ﬁrst two presented
data favouring the Buteyko technique while the third
showed that both interventions produced an equivalent
beneﬁt. The present study is the ﬁrst which was designed todemonstrate in a randomised controlled trial setting
whether the Buteyko technique improved global asthma
control and a reduction in inhaled corticosteroid usage.Methods
Subjects for the study were between 18 and 50 years of age
and had asthma, which had been conﬁrmed by a physician’s
diagnosis and current use of asthma medications or by a
current or previous demonstration of reversibility of their
FEV1 with b2 agonist of at least 12% and no less than 200ml.
They were currently using inhaled corticosteroid for
management of their disease. Their dose of inhaled
corticosteroid should have been stable for at least 6 weeks
prior to entry to the study. They should not have suffered
from an exacerbation of their disease requiring oral
corticosteroid and or a visit to an emergency department
within 2 months of their entry to the study. Smokers and ex-
smokers were not excluded. Subjects with a diagnosis of
another respiratory disease including chronic obstructive
pulmonary disease were excluded.
Eligible subjects were then asked to provide consent prior
to allocation to the Buteyko or the control group. The
consent form informed them that they would be participat-
ing in an asthma breathing techniques study. Their alloca-
tion to the Buteyko or control groups was determined by
opening the next of 200 sequentially numbered sealed
envelopes. Randomisation was achieved by using two equal
lists of random numbers, one for each limb of the study.
These two lists were then combined in a database and
indexed in ascending order. The study number allocated to
each random number and recorded on the sealed envelope
was the random number’s rank in the indexed list. This
process provided approximately equal numbers in each
treatment limb and an unpredictable sequence of alloca-
tion. No adjustment of allocation could be made after the
subject had been enrolled. The two groups had no contact
with each other after randomisation as the two interven-
tions were provided at the same time by different personnel
at different and widely separated venues.
Each patient completed a questionnaire, which contained
questions about their asthma control, asthma medications
and a self-assessment of the extent to which asthma
restricted their lifestyle. We have used this questionnaire
in our centre to assess over 6000 individuals with the
disease. The questions we asked included the following
direct questions about asthma control:
b2 agonist use: ‘‘On average how many doses of your
bronchodilator (reliever medication) (Ventolin, Bricanyl,
salbutamol, Berotec) do you use per day?’’
Waking at night: ‘‘In the past week how many nights has
your sleep been disturbed by asthma?’’
Emergency department visits: ‘‘Have you been to an
emergency room or to a physician for urgent treatment of
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months?’’
Missed work/school: ‘‘Have you missed school or work
because of asthma in the last 3 months?’’
Additional questions were asked in relation to the
patient’s medication including their use of inhaled and oral
corticosteroid, asthma monitoring, use of action plans,
hospital admissions and asthma trigger exposure.
The data obtained from the questionnaire appear to
correlate well with other ﬁndings related to asthma severity
and control.21 The subjects also completed a brief quality of
life questionnaire (Juniper Mini Asthma Quality of Life
Questionnaire).22 Subjects then performed spirometry be-
fore and X10min after salbutamol 200 mg by inhalation.
Each subject was provided with information concerning
the management of their asthma during the study. They
were given an ‘action plan’ designed to help them adjust
their medication in the face of increasing asthma symptoms.
In addition, they received a sheet, which advised them not
to withdraw or reduce their asthma controller medications
without a discussion with their family physician and a letter
to give to their family physician which carried clear
indications for assessing control as deﬁned in this study
and for considering a decrease in controller medication. The
family physicians each received a letter informing them that
their patient was participating in the study and that they
should not alter the standard of medical care that they
ordinarily provided for their patient.Interventions
The Buteyko and the control subjects received instruction,
which was provided to groups of 10–12 subjects in the early
evening on 5 consecutive days. The Buteyko group received
instruction from a trained and internationally accredited
Buteyko practitioner. They were instructed in techniques
designed to reduce (‘normalise’) their ventilation. These
included training to hold their breath at functional residual
capacity (FRC) and instruction to avoid breathing through
the mouth including mouth-taping at night. They were given
a series of exercises, which they were encouraged to
practice repeatedly throughout the day.
The control group was instructed by a registered
physiotherapist with a series of exercises designed to
develop a slow, controlled exhalation, down into FRC toward
their residual volume. Paced breathing was taught during
exercise. In addition, in both groups there was an
opportunity to receive information about asthma from the
instructor and for participants to discuss aspects of asthma.Follow-up
Subjects were contacted at 3 months and at 6 months after
completion of their intervention. They were asked to
complete diary cards for the week before their 3- and 6-
month review. The diary cards were used to support the
questionnaire data regarding asthma control.
Both groups were reassessed 3 and 6 months after the
completion of the intervention to determine whether their
asthma was controlled, their usual daily dose of inhaledcorticosteroid and their quality of life. Spirometry was
repeated within 1 month of the 6-month questionnaire.
Asthma control was deﬁned as achieving all of the
following: Not waking at night with asthma in the week prior to the
assessment. Not needing to use b2 agonist to relieve asthma
symptoms more than 3 times in the week prior to the
assessment. Not having any restriction of their daytime activities
because of asthma in the week prior to their assessment. Not having needed urgent treatment for their asthma (in
an emergency department or a walk-in clinic) since the
previous assessment. Not having missed work/school because of asthma in the
period since their previous assessment.
Analysis and sample size
The primary outcome measurement was asthma control 6
months after completion of the intervention. It was
estimated from data which we have developed in Calgary
and from Canadian statistics that less than 30% of those with
asthma who are taking inhaled corticosteroid will fulﬁll the
criteria for asthma control. It was estimated that 107
subjects in each group would be needed to show with 95%
conﬁdence and 80% power that a threefold greater increase
in the proportion with disease control could be attributed to
the Buteyko intervention. In this model, the percentage in
the control group with disease control would increase from
30% to 40% and in the Buteyko group from 30% to 60%
measured 6 months after the intervention. Secondary
outcome measures would include indices of improved
control, quality of life measurement and reduction in the
dose of inhaled corticosteroid following the intervention.
Although spirometric criteria for control have also been
stipulated, the spirometric data were used only to compare
the change in FEV1 between the two groups as one of the
secondary outcomes.
Statistical analysis was performed by w2 analysis of
categorical data and by paired Student’s t-test for contin-
uous data.
All subjects provided written informed consent prior to
entering the study, which was approved by the Conjoint
Health Research Ethics Board of the University of Calgary.
Results
A total of 182 subjects were screened for the study
(Figure 1). Fifty-three subjects were excluded: 17 failed to
attend for their randomisation visit; 15 withdrew after being
told about the study structure and time commitment; 10
subjects were not using inhaled corticosteroid; 4 subjects
had unstable asthma or were, for reasons not stated,
considered unsuitable for the study; one subject was deaf
and thus considered unable to participate fully in the study
and 6 subjects were inappropriately removed from the study
because of a smoking history of greater than 10 pack years.
The remaining 129 subjects were randomised, 65 to the
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Figure 1
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education in groups of approximately 12 subjects for 5
consecutive evenings and the interventions were completed
during a 6-week period in September and October 2004. The
characteristics of these subjects are presented in Table 1.
There were no signiﬁcant differences in these character-
istics between the two groups. The initial level of disease
control was higher than expected with 40% of the Buteyko
and 44% of the control group showing disease control
(p ¼ 0.7). There was no difference in the average daily
dose of inhaled corticosteroid between the groups and all
were, as required by the study protocol, using inhaled
corticosteroid. The initial quality of life measurement using
the Juniper Mini Asthma Quality of Life questionnaire22 was
similar in the two groups, 4.6 in the Buteyko and 4.7 in the
control group (p ¼ 0.8). There were no differences between
the groups with regard to spirometry expressed as percen-
tage predicted FEV1,
23 83% in the Buteyko and 79% in the
control group (p ¼ 0.3).
For the 6-month follow-up 10 subjects could not be traced
leaving 119 subjects, 56 in the Buteyko and 63 in the controlgroups. Repeated attempts were made by letter and
telephone to reach the missing subjects. Subjects in both
groups enjoyed a signiﬁcant improvement in their asthma
status 6 months after the end of the intervention (Table 2).
The percentage of those with asthma control improved from
40% to 79% (95% CI 68%, 89%) in the Buteyko group and from
44% to 72% (95% CI 60%, 83%) in the control group with no
difference between the groups (p ¼ 0.4). If it was assumed
that all of those not included in the 6-month review had
uncontrolled asthma, the percentage controlled at 6 months
would be 68% for Buteyko and 70% for controls, again, with
no difference between the groups (p ¼ 0.7). Subjects in
both groups showed a clinically and statistically signiﬁcant
(po0.0001) improvement in their quality of life scores (0.96
in the Buteyko and 0.95 in the control group), but there was
no difference between the groups in the degree of
improvement or in their overall quality of life scores.
While both groups had been using similar daily doses of
inhaled corticosteroid on entry to the study, the Buteyko
group who remained for assessment at 6 months had
reduced their average daily dose from 865 to 548 mg of
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Table 1 Characteristics of subjects on entry to study.
Buteyko (n ¼ 65) Control (n ¼ 64) P
Age (years) (SD) 47 (12.5) 48 (12.5) 0.9
Gender (F:M) 49:16 50:14 0.7
Duration of asthma (years) (SD) 22 (15.4) 21 (18.1) 0.8
Non-smokers (%) 46 (71) 46 (72) 0.9
Packyears for smokers and ex-smokers (mean) 6 7 0.6
Asthma controlled (% subjects) 40 44 0.7
Average dose inhaled corticosteroid in beclomethasone equivalent (mg) (SD) 863 (527) 817 (595) 0.6
Subjects with emergency visits in past year 13 10 0.5
FEV1 % predicted
23 (SD) 83 (19.2) 79 (21.6) 0.3
QOL22 4.6 4.7 0.8
Table 2 Status at 6 months after completion of the intervention.
Buteyko (n ¼ 56) Control (n ¼ 63) P
Asthma controlled (% subjects) 79 71 0.4
Average change in daily inhaled corticosteroid
(beclomethasone equivalent (mg) (SD))
317 (588) 56 (575) 0.02
Subjects with Emergency visits in past 6 months 1 4 0.2
Change in FEV1 % predicted
23 (SD) 0.05 (0.472) 0.01 (0.372) 0.6
Change in QOL22 0.96 (1.044) 0.95 (1.154) 1.0
R.L. Cowie et al.730beclomethasone equivalent at 6 months after completion of
the intervention (p ¼ 0.0002) compared with 818 mg down to
762 mg for the control group (p ¼ 0.4). A reduction of
beclomethasone equivalent of 100 mg or more was achieved
by 23 of the Buteyko and 13 of the control group (p ¼ 0.02).
A total of 10 subjects in the Buteyko group and only one in
the control group stopped using a long-acting b2 agonist in
the 6 months after their intervention (p ¼ 0.005) and in the
same period three Buteyko and ﬁve control subjects starting
using a long-acting b2 agonist (NS). No adverse effects were
reported by subjects in the Buteyko or control groups.Discussion
This study, which we believe to be the largest randomised
controlled trial and the ﬁrst to use a global assessment of
asthma control as a primary outcome in a non-pharmacolo-
gical intervention in asthma, failed to show a difference
between the intervention (Buteyko) and control (physiother-
apy) groups. These data suggest that both interventions can
be considered to have been active with a remarkably high
level of disease control in both groups 6 months after
completion of the intervention. The level of disease control
achieved is equivalent to that noted in trials of optimal
asthma medication.2 The Buteyko group differed from the
control group only in their reduction of their daily dose of
inhaled corticosteroid and in the number who stopped using
long-acting b2 agonists. Fourteen of the Buteyko and only
four of the control group had managed to completely
withdraw their inhaled corticosteroid and of these 12 and
four, respectively, enjoyed asthma control.It is difﬁcult to know how to attribute the results of this
study. As with any studies of complementary intervention,
development of a suitable control group intervention was
difﬁcult. In general, physiotherapy is not considered to
contribute to the chronic management of asthma.24 It was
chosen as it was thought important to provide an apparently
credible intervention of similar intensity and duration to
that received by the Buteyko group. The control interven-
tion was disadvantaged by the knowledge, which became
available during the publicity for the study, that one of the
intervention arms involved the Buteyko technique about
which there is considerable awareness from entries on the
World Wide Web. Indeed the entire process of recruiting
subjects to this study was hampered by the acknowl-
edgement to all of those who responded that they would
be randomly allocated to either the Buteyko or the control
groups. Most of those who called did so because of interest
in the Buteyko technique. This initial disadvantage makes
the results in the control group even more remarkable. It
should be noted that the predetermined result from the
intervention was exceeded by both the Buteyko and the
control groups.
It is quite possible that the favourable results reﬂect
aspects other than the interventions which we were testing
and which might include the additional opportunity to
acquire asthma information during approximately 10 h of
contact with the group instructors and with others
with asthma. Nevertheless, whatever the explanation,
these interventions proved to be extremely effective
adjuncts to conventional asthma management. In this
context, the Buteyko method can be recommended
given that it is structured, well-developed and in the
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any adverse effects. Similarly, in centres where there are
expert chest physiotherapy services by physiotherapists
trained in asthma education, a programme of similar
intensity to that provided here could be considered for
patients with asthma, who remain poorly controlled while
taking inhaled corticosteroids.
The frequent explanation of a prolonged beneﬁt from a
control or placebo intervention in asthma studies is that
subjects are recruited when their asthma is poorly con-
trolled and that there is natural regression to the mean.
That explanation seems unlikely in this study; those with
recent asthma exacerbations were excluded and recruit-
ment occurred over several months prior to the onset of the
interventions which were scheduled to occur in a very short
period during which the Australian Buteyko practitioner was
available to provide instruction at our Canadian site.
Furthermore, the method of recruitment and inclusion
criteria were designed to enroll subjects with asthma which
was stable and reﬂected their usual baseline.
Although Buteyko believed that the results from his
technique reﬂected a decrease in ventilation this was not
assessed in this study and has not been demonstrated in
other studies. However, taking the Buteyko theory to its
logical conclusion, any increase in PaCO2 should produce a
demonstrable improvement in spirometry. We were not able
to demonstrate any spirometric response in the Buteyko
group. After 6 months, the post-bronchodilator FEV1 showed
no signiﬁcant change nor any difference between the groups
with a decrease of 80ml in the Buteyko and of 40ml in the
control group.
The Buteyko group did gain the additional beneﬁt of a
reduction of 317 mg beclomethasone equivalent in their
average daily dose of inhaled corticosteroid therapy
compared with a reduction of 56 mg in the control group
(po0.02). This does appear to be a real effect: the Buteyko
instructor was asked not to directly advise her subjects to
adjust their therapy on the grounds that this would interfere
with our ability to assess this important secondary study
outcome. Nevertheless, advice to reduce medications is
given on several Buteyko websites that our subjects in either
of the groups might have accessed.Conclusion
This randomised clinical trial showed that both the Buteyko
and control (physiotherapy) interventions produced a
favourable outcome in that over 70% of the participants
enjoyed asthma control 6 months after completing the
intervention. In addition, the subjects in the Buteyko group
were able to signiﬁcantly reduce their daily doses of inhaled
corticosteroid. The Buteyko technique or an intensive
programme delivered by a chest physiotherapist appear to
provide additional beneﬁt for adult patients with asthma
who are being treated with inhaled corticosteroid.Acknowledgements
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